ERLOTI相关论文
Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case rep
BACKGROUND Squamous cell carcinoma of head and neck (SCCHN) is the fifth most common cancer worldwide. Inhibition of epi......
